The Four-Year Bet on Fixing Huntington's Just Hit a Wall

Wall Street's Verdict Was Swift and Brutal

The stock cratered. uniQure shares dropped roughly 37% to 39% in a single session after the data update. To make matters worse, the FDA had indicated that Phase I/II data versus an external control would not be sufficient as the primary basis for a BLA, turning what was already a bad day into a terrible week.

Barclays downgraded the stock from overweight to equal weight, slashing its price target from $60 to $28.

Not everyone on Wall Street agreed the selloff was justified. Some analysts argued the stock had overshot to the downside, noting that the accelerated approval filing had relied on the stronger three-year data, not the weaker four-year update. But in biotech, confidence is fragile. Once a narrative cracks, it takes more than a note from an optimistic analyst to patch it.

Why This Matters Beyond One Company

Huntington's disease is genetic, progressive, and devastating. A single mutation in the HTT gene causes brain cells to produce a toxic version of the huntingtin protein. Over years, it destroys neurons in the striatum, a brain region critical for movement and cognition. Patients gradually lose the ability to walk, talk, think, and eventually care for themselves.

And right now, there is no approved therapy that slows or stops it. Everything available treats symptoms: drugs like deutetrabenazine and valbenazine control involuntary movements (chorea), while antipsychotics and antidepressants manage psychiatric symptoms. Multidisciplinary rehab helps with quality of life. But nothing touches the underlying disease.

That's why AMT-130 mattered so much. It was designed to attack the root cause. Delivered directly into the brain through MRI-guided surgery, the gene therapy uses an AAV-delivered microRNA to "gum up" production of the toxic huntingtin protein. One surgery, potentially lasting benefit. Think of it like installing a permanent filter in a contaminated water supply rather than just treating people who drink from it.

Huntington's Has Broken Hearts Before

If this story feels familiar, it should. The biggest previous attempt to modify Huntington's disease was tominersen, an antisense oligonucleotide developed by Roche and Ionis. That drug also lowered huntingtin levels in the brain. It also generated early optimism. And it also failed.

In 2021, Roche stopped dosing in its Phase 3 GENERATION HD1 trial after an independent review found patients on the more frequent dosing schedule were actually doing worse. Some developed hydrocephalus. The drug appeared to overshoot its target. Roche spent years trying to rescue the program in a narrower patient population, but by 2026, it pulled the plug on GENERATION HD2 as well. Tominersen hit its biomarker endpoints (it did lower huntingtin) but failed on clinical efficacy. Patients didn't get better.

The lesson was sobering: lowering mutant huntingtin protein isn't automatically enough. Dose matters. Timing matters. Which patients you treat matters. And biological plausibility doesn't guarantee clinical success.

AMT-130's stumble at four years raises an uncomfortable echo of that lesson. The three-year data suggested the therapy could be different. The four-year data suggests the story is more complicated than anyone hoped.

The Race Isn't Over (But Nobody's Winning Yet)

Despite the setback, the Huntington's pipeline hasn't gone dark. Several companies are still chasing disease modification through different approaches.

PTC Therapeutics, in collaboration with Novartis, is developing votoplam (PTC518), an oral splicing modifier that lowers huntingtin production. The big advantage: patients swallow a pill instead of undergoing brain surgery. Wave Life Sciences is working on WVE-003, which tries to selectively silence only the mutant copy of the HTT gene while leaving the healthy copy alone. Alnylam has ALN-HTT02, an RNA interference therapy targeting HTT. And Skyhawk Therapeutics has SKY-0515, another oral splicing modulator that entered Phase II/III studies.

Roche's tominersen is technically still alive in some form, though calling it a comeback candidate requires generous use of the word "comeback."

Each of these approaches carries its own risks. Oral drugs are easier to administer but may not concentrate well enough in the brain. Allele-selective therapies are elegant in theory but unproven in practice. Gene therapies offer durability but require invasive delivery. There's no clear winner, just a field of contenders still searching for the right combination of mechanism, dose, and patient selection.

What This Means for Patients and Families

For the roughly 30,000 Americans living with Huntington's disease (and many more who carry the gene and will eventually develop symptoms), another setback lands differently than it does for investors. Wall Street moves on to the next ticker. Families don't have that luxury.

The community response to the AMT-130 data is likely a mix of disappointment and weary resolve. Huntington's families are, unfortunately, experienced at processing bad clinical news. They've watched tominersen fail. They've seen smaller programs quietly fold. They know that "promising early data" is not a guarantee, and they also know that the field needs to keep swinging.

Advocacy groups have long pushed for better supportive care alongside drug development, and moments like these reinforce why. Even if a disease-modifying therapy arrives eventually, patients need better psychiatric support, cognitive rehabilitation, and caregiver resources now. The pipeline is years away from delivering; the unmet need is today.

The Uncomfortable Truth About Gene Therapy's Hardest Test

The brain remains the toughest organ to treat. Getting a therapy past the blood-brain barrier, into the right cells, at the right dose, with durable effect and acceptable safety, is arguably the hardest challenge in all of drug development. Huntington's disease, with its slow progression and complex biology, makes that challenge even harder.

AMT-130 isn't dead. uniQure will likely continue to analyze the data, argue its case to regulators, and explore paths forward. But the clean narrative of a one-time gene therapy cure for Huntington's disease has gotten considerably messier.

Sometimes in biotech, the most important data isn't the first readout. It's the follow-up that tests whether early promise holds. For AMT-130, year three was the promise. Year four was the test.

And the test was not kind.

The $116.7M Bet on the Immune System's Secret Police Force

TRex Bio just went public with $117 million and Eli Lilly as its biggest shareholder, all to boost the immune system's own peacekeeping cells. The Treg therapy space is heating up fast, and the race to reinvent autoimmune treatment is officially on.